✦ LIBER ✦

Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide

✍ Scribed by María Teresa Cibeira; Carlos Fernández de Larrea; Alfons Navarro; Tania Díaz; Dolors Fuster; Natalia Tovar; Laura Rosiñol; Mariano Monzó; Joan Bladé

Book ID: 113773409
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 332 KB
Volume: 35
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2011.02.009

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of single-agent bortezomib vs.

Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison

✍ H. Miles Prince; Michael Adena; Dell Kingsford Smith; Judy Hertel 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 593 KB

Impact of high-risk cytogenetics and pri

Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone

✍ Avet-Loiseau, H; Soulier, J; Fermand, J-P; Yakoub-Agha, I; Attal, M; Hulin, C; G 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 313 KB

Single nucleotide polymorphisms in the p

Single nucleotide polymorphisms in the promoter region of theIL1Bgene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib

✍ Annette J. Vangsted; Tobias W. Klausen; Niels Abildgaard; Niels F. Andersen; Pet 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 509 KB

An open-label, single-arm, phase 2 study

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

✍ Ravi Vij; David S. Siegel; Sundar Jagannath; Andrzej J. Jakubowiak; Alexander Ke 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 198 KB

Long-term follow-up on overall survival

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

✍ Dimopoulos, M A; Chen, C; Spencer, A; Niesvizky, R; Attal, M; Stadtmauer, E A; P 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 164 KB